Cancer Institute Director. Head & Neck Surgeon. Clinical Researcher focused on #immunotherapy. Relentlessly working to #FinishCancer @Providence Tweets my own
Joined December 2015
- Tweets 3,268
- Following 674
- Followers 2,531
- Likes 7,555
704 Photos and videos
Pinned Tweet
I am deeply honored to succeed Dr. Urba & I am committed to building upon his legacy of transformational immuno-oncology research & a world-class cancer center dedicated to translating the next generation of immunotherapies from lab bench to the bedside. @ChilesResearch
14 Nov 2024
Providence is excited to announce Bryan Bell, M.D., as executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute @ChilesResearch. Walter Urba, M.D., Ph.D., wll retire at the end of the year. blog.providence.org/regional…
14
4
54
7,669
An inspiring “Evening of Laurels”, celebrating @NobelPrize laureate Dr. Mary Brunkow of the @isbsci, part of the @providence family of organizations.
It was a privilege to join colleagues and friends in recognizing Dr. Brunkow’s extraordinary contributions to science.
1
6
341
Farewell Chicago and #ASCO2026. Great week of science and better treatment for patients with cancer.
@ASCO
#FinishCancer
@providence
#HoodToCoast
1
7
470
1
1
201
1
1
115
Excited to see the updated first-in-human #ASCO2026 data for KLN-1010, an in vivo BCMA CAR-T therapy with promising early results in multiple myeloma.
Proud that @Providence Cancer Institute was the first site in the U.S. to open and enroll patients to this groundbreaking study.
2
7
756
R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) retweeted
Jun 1
Another major advance vs cancer! @ASCO #ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
ascopubs.org/doi/10.1200/JCO…
31
511
2,043
483,143
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM
#ASCO26 | @ASCO
ALT A two-panel line graph shows overall survival in two populations, comparing darovasertib (blue line) and chemotherapy (gray line) treatments. Panel A depicts the RAS G12 population, while Panel B shows the overall population. Hazard ratios and confidence intervals are detailed in each panel.
ALT This image shows two line graphs titled "Progression-free Survival in the RAS G12 Population" and "Progression-free Survival in the Overall Population." Both graphs compare survival rates over 13 months between two groups: one receiving darovasertib and the other receiving chemotherapy. Accompanying the graphs are tables detailing the number of events and patients at risk for each treatment group.
8
348
1,197
69,111
Proud week for the Earle A. Chiles Research Institute at #ASCO2026 🧬
Highlights from our team at @providence:
▪️ M3T01 (FasL inhibitor) — conceived, developed & manufactured entirely at Providence, now through dose escalation & entering combo with anti-PD-1 (Taylor, Leidner)
1
4
245
▪️ NT-175 eTCR T-cell therapy — 47% ORR including 83% in pancreatic cancer (Leidner)
▪️ KEYNOTE-942 5-yr update — personalized neoantigen vaccine pembro, durable benefit in resected melanoma (Taylor)
1
3
218
▪️ ARROW final analysis — pralsetinib in RET-altered thyroid cancer, 76% 2-yr DOR (Taylor)
▪️ PIKALO-1 tersolisib update — PI3Kα inhibitor in breast cancer (Page)
▪️ TAK-188 anti-CCR8 ADC — Treg-depleting therapy in solid tumors (Sanborn)
#FinishCancer @providence 🙏
2
233
Great to be in Chicago for #ASCO2026 and the meeting is already delivering.
Today’s plenary presentation of the Phase III daraxonrasib trial showed a nearly doubling of survival in metastatic pancreatic cancer (13.2 vs 6.7 months). A landmark result for patients & the field.
7
244
R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) retweeted
May 31
This is not simply a new pancreatic cancer drug.
It is a reminder that even “undruggable” biology can become treatable with persistence.
Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists
24
277
1,355
192,315
At this year’s Creating Hope event, I had the privilege of sharing a glimpse of the future we are building at @Providence Cancer Institute.
Thank you to everyone who joined us in imagining—and helping create—a future where we #finishcancer .
vimeo.com/1196060632?fl=pl&f…
1
160
💥Now open @providence:
IMA203, a novel PRAME-targeted TCR-T cell therapy designed for patients w advanced solid tumors. Proud of our teams advancing next-gen cellular therapies & expanding access to innovative clinical trials for patients across the PNW. blog.providence.org/regional…
1
122
At @Providence Cancer Institute, Dr. Carlo Bifulco
is helping lead a precision oncology revolution, advancing how cancer is diagnosed and treated through comprehensive genomic profiling, digital pathology and responsible use of artificial intelligence. linkedin.com/posts/providenc…
2
146
Grateful to our donors, researchers, clinicians, patients & partners who are helping us create hope. From AI-driven pathology & precision oncology to early detection, cellular therapies, and first-in-human clinical trials, the future is what we make it. #FinishCancer
@providence
4
160
@providence receives esteemed NIH grant for ‘paradigm shift’ in head and neck cancer treatments providence.org/news/uf/69300…
1
1
13
585
Grateful for the warm welcome & outstanding exchange with @JosephMCurryMD & the team at the @JeffersonUniv.
Inspiring to connect around our shared mission to advance translational science & deliver cutting-edge cancer care. Looking forward to continued collaboration
@providence
2
254
The FDA has approved teclistamab (BCMA×CD3 bispecific) daratumumab (CD38)—bringing powerful immune-based therapy and another inflection point in survival outcome.
A major step toward durable remissions—and potentially functional cure.
#FinishCancer
@providence
4
10
1,167
Real-world data shows WGS drives treatment decisions and improves outcomes beyond standard panels. It’s time for payers & legislators to evolve coverage & privacy policy to support comprehensive profiling & ensure equitable access to precision oncology. nature.com/articles/s41591-0…
1
176